Literature DB >> 16517094

Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level.

Barby Pickett1, John Kurhanewicz, Jean Pouliot, Vivian Weinberg, Katsuto Shinohara, Fergus Coakley, Mack Roach.   

Abstract

PURPOSE: To evaluate the metabolic response by comparing the time to resolution of spectroscopic abnormalities (TRSA) and the time to prostate-specific antigen level in low-risk prostate cancer patients after treatment with three-dimensional conformal external beam radiotherapy (3D-CRT) compared with permanent prostate implantation (PPI). Recent studies have suggested that the treatment of low-risk prostate cancer yields similar results for patients treated with 3D-CRT or PPI. METHODS AND MATERIALS: A total of 50 patients, 25 in each group, who had been treated with 3D-CRT or PPI, had undergone endorectal magnetic resonance spectroscopy imaging before and/or at varying times after therapy. The 3D-CRT patients had received radiation doses of > or =72 Gy compared with 144 Gy for the PPI patients. The spectra from all usable voxels were examined for detectable levels of metabolic signal, and the percentages of atrophic and cancerous voxels were tabulated.
RESULTS: The median time to resolution of the spectroscopic abnormalities was 32.2 and 24.8 months and the time to the nadir prostate-specific antigen level was 52.4 and 38.0 months for the 3D-CRT and PPI patients, respectively. Of the 3D-CRT patients, 92% achieved negative endorectal magnetic resonance spectroscopy imaging findings, with 40% having complete metabolic atrophy. All 25 PPI patients had negative endorectal magnetic resonance spectroscopy imaging findings, with 60% achieving complete metabolic atrophy.
CONCLUSION: The results of this study suggest that metabolic and biochemical responses of the prostate are more pronounced after PPI. Our results have not proved PPI is more effective at curing prostate cancer, but they have demonstrated that it may be more effective at destroying prostate metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517094     DOI: 10.1016/j.ijrobp.2005.11.037

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.

Authors:  M Keyes; G Merrick; S J Frank; P Grimm; M J Zelefsky
Journal:  Brachytherapy       Date:  2017-01-16       Impact factor: 2.362

Review 2.  Long-term urinary adverse effects of pelvic radiotherapy.

Authors:  Sean P Elliott; Bahaa S Malaeb
Journal:  World J Urol       Date:  2010-10-20       Impact factor: 4.226

Review 3.  Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity.

Authors:  Johnny Kao; Jamie A Cesaretti; Nelson N Stone; Richard G Stock
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

Review 4.  MR imaging of the prostate in clinical practice.

Authors:  Yousef Mazaheri; Amita Shukla-Dave; Ada Muellner; Hedvig Hricak
Journal:  MAGMA       Date:  2008-09-16       Impact factor: 2.310

Review 5.  The role of metabolic imaging in radiation therapy of prostate cancer.

Authors:  V Y Zhang; A Westphalen; L Delos Santos; Z L Tabatabai; K Shinohara; D B Vigneron; J Kurhanewicz
Journal:  NMR Biomed       Date:  2013-08-12       Impact factor: 4.044

6.  Carbon Ion Radiotherapy Induce Metabolic Inhibition After Functional Imaging-Guided Simultaneous Integrated Boost for Prostate Cancer.

Authors:  Yulei Pei; Renli Ning; Wei Hu; Ping Li; Zhenshan Zhang; Yong Deng; Zhengshan Hong; Yun Sun; Xiaomao Guo; Qing Zhang
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.